Divis Labs surges as USFDA to lift import alert at Visakhapatnam facility

Govt proposes to bring fixed-dose combinations under price control
Divis Laboratories surged 20% to Rs 816 on BSE in intra-day trade after the company said it has been informed by the United State Food and Drug Administration (US-FDA) that it will lift the import alert 99-32 imposed on the company's Unit-II at Visakhapatnam.

The US-FDA had issued an import alert under clauses 99-32 and 66-40 in March of 2017 and a warning letter in May of 2017 for the company’s Vishakhapatnam facility.

“Divi's Laboratories has filed detailed responses and given updates to the Form-483 and the warning letter within the stipulated time. Divi's Laboratories, along with its external consultants, specialists and subject matter experts, has taken up appropriate remediation measures to address the concerns raised by US-FDA,” the company said in a BSE filing.

The company awaits further action from US-FDA in this regard, it added.

At 11:59 am; the stock was up 15% at Rs 783 on BSE, as compared to 0.62% rise in the S&P BSE Sensex. Around 1.42 million shares changed hands on the counter on BSE so far.

The stock had hit a 52-week low of Rs 533 on May 29, 2017 in intra-day trade after the US drug regulator had issued a warning letter for its unit-II at Visakhapatnam.

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel